Challenges facing the control of leprosy in the Indian context

Annals of the Academy of Medicine Singapore

Volumn 39, Issue 1, 2010, Pages 1-3

  Shetty, Vanaja Prabhaker ^a  

^a FOUNDATION FOR MEDICAL RESEARCH   (India)

Author keywords

[No Author keywords available]

Indexed keywords

BANGLADESH; DISEASE CONTROL; DISEASE SURVEILLANCE; EDITORIAL; HEALTH EDUCATION; HEALTH PROGRAM; INDIA; LEPROSY; MYCOBACTERIUM LEPRAE; NERVE FUNCTION; PREVALENCE; WORLD HEALTH ORGANIZATION;

EID: 75749143085     PISSN: 03044602     EISSN: 29724066     Source Type: Journal    
DOI: None     Document Type: Editorial

References (24)

1. Global leprosy situation, beginning of 2008. Wkly Epidemiol Rec 2008;83:293-300.
2. Expert committee on leprosy; first report. World Health Organ Tech Rep Ser 1953;71:1-28.
3. Shetty S, Nandakishore, Shetty JN. National Leprosy Eradication Program. Indian J Dermatol 1997;42:55-64.
4. Chemotherapy of leprosy for control programmes: report of a WHO Study Group. World Health Organ Tech Rep Ser 1982;675:1-33.
5. Dhillon GPS, Barkakaty BN. National Leprosy Eradication Program in India: Achievements and Deficiencies. Health Administrator, Vol. XVIII:4-7.
6. Elimination of leprosy: resolution of the 44th World Health Assembly. Geneva: World Health Organization, 1991. Resolution No. WHA 44.9.
7. World Health Organization. The final push towards elimination of leprosy: strategic plan 2000-2005, Geneva 2000; WHO/CDS/CPE/CEE/2000.1.
8. National programme managers for leprosy elimination - Report of an Inter-country meeting, Katmandu, Nepal, 6-8th January 2005, WHO Regional Office for South-east Asia.
9. Announcement: India achieves national elimination of leprosy. Indian J Lepr 2006;78:101.
10. Shortening duration of treatment of multibacillary leprosy. Wkly Epidemiol Rec 1997;72:125-8.
11. World Health Organization. Global Strategy for Further Reducing the Leprosy Burden and Sustaining Leprosy Control Activities 2006-2010. Geneva: WHO, 2005. WHO/ CDS/ CPE/ CEE/ 2005.53.
12. Shetty VP, Thakar UH, D'souza E, Ghate SD, Arora S, Doshi RP, et al. Detection of previously undetected leprosy cases in a defined rural and urban area of Maharashtra, Western India. Lepr Rev 2009;80:22-33.
13. Moet FJ, Schuring RP, Pahan D, Oskam L, Richardus JH. The prevalence of previously undiagnosed leprosy in the general population of northwest Bangladesh. PLoS Negl Trop Dis 2008;2:e198
14. Grossi MAF, Moschioni C, Lambertucci JR, Antunes CMF. Estimation of hidden prevalence of leprosy during the period 2001-2005 in Minas Gerais, Brazil. Proceedings of the 17th International Leprosy Congress, Hyderabad, February 2008.
15. Britton WJ, Lockwood DNJ. What is necessary to eradicate leprosy? Lancet 2004;363:1209-19.
16. Centers for disease control and prevention. Recommendation of the International Task Force for Disease Eradication. MMWR Recomm Rep 1993;42:1-38.
17. Shetty VP, Mistry NF. Key issues related to bacterial persistors. In: Sood OP, Rattan A, editors. Leprosy Elimination: Critical Issues. New Delhi: Ranbaxy Science Foundation, 2002:177-86.
18. Shetty VP, Khambati FA, Ghate SD, et al. The effect of corticosteroids usage on bacterial killing, clearance and nerve damage in leprosy; Part 3 - Study of two comparable groups of 100 multibacillary (MB) patients each, treated with MDT + steroids versus MDT alone, assessed at 6 months post - release from 12 months MDT. Lepr Rev 2010;81 (in press).
19. Maeda S, Matsuoka M, Nakata N, Kai M, Maeda Y, Hashimoto K, et al. Multidrug resistant Mycobacterium leprae from patients with leprosy. Antimicrob Agents Chemother 2001;45:3635-9.
20. Shetty VP, Wakade AV, Ghate S, Pai VV, Ganapati R, Antia NH. Viability and drug susceptibility testing of M. leprae using mouse footpad in 37 relapse cases of leprosy. Int J Lepr Other Mycobact Dis 2003;71:210-7.
21. WHO. Guidelines for Global Surveillance of Drug Resistance in Leprosy. WHO 2009, SEA-GLP-2009.2.
22. De Rossi, Ainsa JA, Riccardi G. Role of mycobacterial efflux transporters in drug resistance: an unresolved question. FEMS Microbiol Rev 2006;30:36-52.
23. Capadia GD, Shetty VP, Khambati FA, Ghate SD. Effect of corticosteroid usage combined with multi-drug therapy on nerve damage assessed using nerve conduction studies: A prospective cohort study of 365 untreated multibacillary (MB) leprosy patients. J Clin Neurophysiol 2010;27(in press).
24. Rao PS, Sugumaran DS, Richard J, Smith WC. Multi-centre, double blind, randomized trial of three steroid regimens in the treatment of type 1 reactions in leprosy. Lepr Rev 2006;77:25-33.